Pharma Medical News

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

ACTEMRA inhibits progression of joint destruction in RA patients by over 80% compared to methotrexate alone
Roche, 10/19/09

Two–year data from the LITHE study, being presented at the American College of Rheumatology, show that, with long–term use, patients with rheumatoid arthritis treated with ACTEMRA plus methotrexate suffered 81% less damage to their joints compared to those treated with MTX, the current standard therapy, alone1. For patients, this means that their joint damage is significantly reduced, and that they can therefore continue to enjoy their lives without the evolving disability usually associated with the disease.

<< Previous
FDA approves Cervarix, GlaxoSmithKlines cervical cancer vaccine

Next >>
U.S. Food and Drug Administration approves CRESTOR for use in...